{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-120365","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2023-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.902759+00:00","generated_at":"2026-06-07T22:35:37.078147+00:00","sec_items":["5.02"],"event_type":"other","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sagimet Biosciences grants RSUs to executives post-IPO; CEO Happel receives 624,910 units","bullets":["Board approved RSU grants: CEO David Happel (624,910), Eduardo Martins (89,570), George Kemble (150,750).","RSUs vest 25% on first anniversary of IPO closing, remainder over three years, subject to continued service.","Compensation Committee engaged Compensia to align executive compensation with public-company peers."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-120365","json":"https://secwatch.observer/filing/0001104659-23-120365.json","markdown":"https://secwatch.observer/filing/0001104659-23-120365.md","text":"https://secwatch.observer/filing/0001104659-23-120365.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923120365/0001104659-23-120365-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923120365/tm2331242d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T22:35:37.078147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}